Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.
about
Invasive mold infections in solid organ transplant recipientsAntifungal Prophylaxis in Immunocompromised PatientsPosaconazole: an oral triazole with an extended spectrum of activityTrypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.Exophiala spinifera as a cause of cutaneous phaeohyphomycosis: case study and review of the literature.Isavuconazole: A New Option for the Management of Invasive Fungal Infections.Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Targeted versus universal antifungal prophylaxis among liver transplant recipientsSafety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.Ontogeny and sorafenib metabolism.Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.Invasive fungal infections and antifungal therapies in solid organ transplant recipients.Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents.Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management.Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.Voriconazole therapeutic drug monitoring: focus on safety.Management of drug and food interactions with azole antifungal agents in transplant recipients.Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.Antifungal prophylaxis in solid organ transplant recipients.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Current concepts in antifungal pharmacology.Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.Safety and interactions of new antifungals in stem cell transplant recipients.Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism.Antifungal prophylaxis in liver transplantation: a systematic review and network meta-analysis.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Duration of prophylaxis against fungal infection in kidney transplant recipients.Salvage Treatment of Mucormycosis Post-Liver Transplant With Posaconazole During Sirolimus Maintenance Immunosuppression.Evaluation of the effect of fluconazole on the pharmacokinetics of cyclosporin A in healthy dogs after a single dose and at steady-state.Immunosuppression in pediatric liver transplant recipients: Unique aspects.An update on the safety and interactions of antifungal drugs in stem cell transplant recipients.Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4.Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation.Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole.Evaluation of the Interaction of Intravenous and Oral Voriconazole with Oral Cyclosporine in Iranian HSCT Patients.Posaconazole: a next-generation triazole antifungal.
P2860
Q26823811-51DB9328-AAF0-4CA6-9EEB-576F4C8CC3A8Q28074168-98F2966D-4053-4F4B-B7D0-B1AF4DB67E75Q28291282-539CED3F-F777-4C4F-9CB5-B8AE5569EDE4Q28553573-FE54C151-26F9-454E-BB4E-7AE1F864890AQ30151881-720FBF7E-C5D5-4C40-97D0-081FE3CB978DQ34137709-685CA845-6D53-47C4-B7B7-1367FC87AA9BQ34474946-33B136AD-0197-4ADE-BB7D-D606DA6586B0Q34510280-F0187764-8C25-4235-9572-F7ADA4930643Q35026481-9A9F40FB-C030-4C95-AC7B-738ADCFA9074Q35194743-58A9EC65-47BE-48F9-9619-0ECF29023AF7Q35231368-3068714E-DB2C-4BC2-99C7-56B5AE14058EQ36375706-B60CDCEC-A68E-4C8D-9388-94F60FFFA84EQ36668891-6B988982-3685-4880-A776-7B54A52772F9Q36872848-7C807D45-2E46-43DF-9C32-1D563DA66982Q37038199-511729A5-5678-4712-BB65-FE1D82B75B1FQ37157893-C098CF5F-127F-46A5-BEE5-9F5252461F29Q37173189-757743E6-0FD3-4E83-A9D0-4213F0A29607Q37621550-1476850F-B05D-48FC-A15A-97C46B6D7931Q37658869-029CC733-5DE8-434A-B733-F4F4A135A33BQ37775009-B99E4066-2401-467D-8D92-BEFF0C8D5DA1Q37816399-F09953E6-41F9-439A-B0E3-7380C8680E04Q37879201-B9E0AC2E-8A89-45BA-88F0-0D846E3A6871Q37904672-BF859071-AB36-4971-B0CD-D6E97737425FQ37908856-B132EAA4-F4B1-4EBF-8FB8-D48B8686968CQ37945308-7F878564-8B75-4D71-9F8C-DD2244BE9869Q38036740-3EAE6017-5254-414D-BB36-5ACD4BE1950CQ38183877-29433E6C-B199-4465-9C59-292FE2C54554Q38268056-8CC67356-F950-42F4-8261-6FE727EF2BD4Q38284468-649FA05C-A0C9-41B0-836F-F6BF686938FCQ38644817-FEC9A9E5-42BA-47EE-9FF6-CCF03A6F5954Q38662303-F086AE1A-2B2C-43F4-8E78-19DBFBD20B65Q38728750-880CCB84-5D62-4477-AED7-1E15830B5C61Q38825266-F3F93F7F-1597-4DD5-8F4E-6B3E4095D918Q39016575-CA5A7EC5-2C78-47FC-9E96-F95C14AE68C8Q39048531-32ABDAA5-77D4-4EFA-9342-1054E9451EE5Q39443748-070C863A-2F5B-46F4-8DBD-04197C0E95FEQ39634880-2011521E-FB1A-4381-B355-7D6113848DAEQ40148350-F2D73073-C37D-48B7-9601-C0F182332FF3Q40171742-0322E816-F155-4030-BF04-FECA1E672129Q40188974-63EA6430-3A60-4E32-B1FE-22ADA5142B81
P2860
Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Factors influencing the magnit ...... and select immunosuppressants.
@ast
Factors influencing the magnit ...... and select immunosuppressants.
@en
type
label
Factors influencing the magnit ...... and select immunosuppressants.
@ast
Factors influencing the magnit ...... and select immunosuppressants.
@en
prefLabel
Factors influencing the magnit ...... and select immunosuppressants.
@ast
Factors influencing the magnit ...... and select immunosuppressants.
@en
P2860
P356
P1433
P1476
Factors influencing the magnit ...... and select immunosuppressants
@en
P2093
Daryl D DePestel
Peggy L Carver
P2860
P304
P356
10.1592/PHCO.26.12.1730
P407
P577
2006-12-01T00:00:00Z